AN2 Therapeutics, Inc. (ANTX) Dividend History

AN2 Therapeutics, Inc. (ANTX) is a biopharmaceutical company focused on developing targeted therapies for neurodegenerative and neurological disorders. The company’s research centers on innovative approaches to treat diseases such as Alzheimer's and other cognitive impairments, aiming to address unmet medical needs through novel small molecule and biologic programs.

1800 El Camino Real, Suite D, Menlo Park, CA, 94027
Phone: (650) 331-9090
Website: https://www.an2therapeutics.com
Dividend Yield: 233.33%
Dividend Frequency: Quarterly

Dividend History

Pay Date Amount Ex Dividend Date Record Date
May 01, 2018 $0.66 04/12/2018 04/15/2018
February 01, 2018 $0.66 01/11/2018 01/15/2018
November 01, 2017 $0.66 10/12/2017 10/15/2017
August 01, 2017 $0.66 07/12/2017 07/15/2017
May 01, 2017 $0.66 04/11/2017 04/15/2017
Show more

Dividends Summary

  • AN2 Therapeutics, Inc. has issued 12 dividend payments over the past 3 years
  • The most recent dividend was paid 2641 days ago, on May 1, 2018
  • The first recorded dividend was paid on August 3, 2015
  • The highest dividend payout was $0.66 per share
  • The average dividend over this 3 year span is $0.65 per share
  • AN2 Therapeutics, Inc. has increased its dividend payments by 13.92% since 2015

Company News

  • Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround

    AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

    Zacks Investment Research
  • ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for monday.com Ltd. (NASDAQ: MNDY) from $238 to $242. Keybanc analyst Jason Celino maintained an Overweight rating. monday.com shares dipped 10.1% to close at $212.01 on Monday. See how other analysts view this stock. Needham cut G1 Therapeutics, Inc. (NASDAQ: GTHX) price target from $14 to $12. Needham analyst Gil Blum maintained a Buy rating. G1 Therapeutics shares fell 1.1% to close at $4.48 on Monday. See how other analysts view this stock. Needham boosted the price target for Cadence Design Systems, Inc. (NASDAQ: CDNS) from $315 to $320. Needham analyst Charles Shi maintained a Buy rating. Cadence Design shares fell 1.7% to close at $306.58 on Monday. See how other analysts view this stock. B. Riley Securities cut The Children's Place, Inc. (NASDAQ:

    Benzinga
    Featured Companies: CDNS LSCC MNDY PLCE PYPL TRMB
  • AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

    MENLO PARK, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today provided an update on the ex-U.S. development plan for epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common form of non-tuberculous mycobacterial (NTM) lung disease.

    GlobeNewswire Inc.
  • Stocks To Watch: Twitter Twists + Earnings For Netflix, J&J And Tesla

    Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week

    Seeking Alpha
    Featured Companies: AXP HPE JNJ LULU NFLX PTLO TSLA
Page data last updated 07/23/2025 17:00:42 UTC Dividend yield is calculated using only dividends that have already been paid. Future or declared dividends are not included